Literature DB >> 1596939

Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

A S Koo1, C Armstrong, B Bochner, T Shimabukuro, C L Tso, J B deKernion, A Belldegrum.   

Abstract

Interleukin-6 (IL-6) is a recently characterized pleiotropic cytokine with antitumor activity. We investigated the production of IL-6 by renal cell cancer (RCC) and the growth effects of IL-6 on RCC. Using immunoperoxidase staining, cytoplasmic IL-6 was detected in four of four renal tumor lines and in tumor cells from freshly nephrectomized RCC. We found that IL-6 mRNA was expressed at basal culture conditions by seven of ten RCC tumor lines tested. Biologically active IL-6, as measured by the B9 assay, was produced by all ten RCC tumor lines. The addition of tumor necrosis factor alpha (TNF alpha) significantly augmented the expression of IL-6 mRNA in five RCC tumor lines (P less than 0.05). The combination of interferon gamma IFN gamma and TNF alpha further enhanced the augmented IL-6 mRNA accumulation seen with TNF alpha alone (P less than 0.05). TNF alpha also significantly stimulated the production of biologically active IL-6 (P less than 0.01). Furthermore, IFN gamma and TNF alpha were found to enhance IL-6 bioactivity synergistically (P less than 0.05). The growth effects of IL-6 on RCC were also investigated in two experimental systems: IL-6 was found to stimulate proliferative responses in six of six RCC tumor lines as measured by thymidine-uptake assays; however, only one of six tumor lines displayed an increase in proliferative response of greater than 21% (113%). The growth effect of IL-6 was further tested in clonogenic assays. One of the tumor lines tested displayed an enhanced growth response of up to 200%. We conclude that IL-6 is produced by RCC; this production is enhanced by TNF alpha with synergistic effects seen with IFN gamma at both mRNA and protein levels. In turn, IL-6 may have a modest stimulatory growth effect on certain RCC tumor lines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596939     DOI: 10.1007/bf01741856

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  37 in total

1.  In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma.

Authors:  P G Brouckaert; G G Leroux-Roels; Y Guisez; J Tavernier; W Fiers
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

2.  Serum levels of interleukin-6 and acute phase responses.

Authors:  M W Nijsten; E R de Groot; H J ten Duis; H J Klasen; C E Hack; L A Aarden
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

3.  Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2.

Authors:  L Chen; Y Mory; A Zilberstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis.

Authors:  C W Löwik; G van der Pluijm; H Bloys; K Hoekman; O L Bijvoet; L A Aarden; S E Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1989-08-15       Impact factor: 3.575

5.  Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.

Authors:  J Van Damme; J Van Beeumen; B Decock; J Van Snick; M De Ley; A Billiau
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

6.  Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor.

Authors:  J Content; L De Wit; P Poupart; G Opdenakker; J Van Damme; A Billiau
Journal:  Eur J Biochem       Date:  1985-10-15

7.  Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1).

Authors:  C Miyaura; K Onozaki; Y Akiyama; T Taniyama; T Hirano; T Kishimoto; T Suda
Journal:  FEBS Lett       Date:  1988-07-04       Impact factor: 4.124

8.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

9.  Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha.

Authors:  A G Leary; K Ikebuchi; Y Hirai; G G Wong; Y C Yang; S C Clark; M Ogawa
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  28 in total

1.  A possible growth factor role of IL-6 in neuroectodermal tumours.

Authors:  E Candi; R A Knight; A Spinedi; P Guerrieri; G Melino
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.

Authors:  Hironori Fukuda; Toshio Takagi; Tsunenori Kondo; Kazuhiko Yoshida; Satoru Shimizu; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2018-01-05       Impact factor: 3.402

Review 3.  Growth factors and renal cancer: characterization and therapeutic implications.

Authors:  J H Mydlo
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Authors:  Yosuke Yasuda; Kazutaka Saito; Takeshi Yuasa; Sho Uehara; Naoko Kawamura; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka; Shinya Yamamoto; Tetsuo Okuno; Junji Yonese; Kazunori Kihara; Yasuhisa Fujii
Journal:  Int J Clin Oncol       Date:  2017-07-21       Impact factor: 3.402

5.  Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib.

Authors:  Tetsuo Fujita; Ken-Ichi Tabata; Daisuke Ishii; Kazumasa Matsumoto; Kazunari Yoshida; Masatsugu Iwamura
Journal:  Mol Clin Oncol       Date:  2017-03-20

6.  The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study.

Authors:  B Paule; J Belot; C Rudant; C Coulombel; C C Abbou
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

7.  Interleukin-6 stimulates cell proliferation of rat pituitary clonal cell lines in vitro.

Authors:  T Sawada; K Koike; Y Kanda; H Ikegami; H Jikihara; T Maeda; Y Osako; K Hirota; A Miyake
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

8.  Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Authors:  Yosuke Yasuda; Kazutaka Saito; Takeshi Yuasa; Shinichi Kitsukawa; Shinji Urakami; Shinya Yamamoto; Junji Yonese; Shunji Takahashi; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2012-08-11       Impact factor: 3.402

9.  Coexistence of subacute thyroiditis and renal cell carcinoma: a paraneoplastic syndrome.

Authors:  Ekrem Algün; Süleyman Alici; Cevat Topal; Serdar Ugras; Reha Erkoç; M Emin Sakarya; Nese Ozbey
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

10.  Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Kenji Omae; Toshio Takagi; Jumpei Iizuka; Hirohito Kobayashi; Kazunari Tanabe
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.